NEW YORK (Standard&Poor's) July 26, 2012--Standard&Poor's Ratings Services said today that it assigned ratings to issues filed by New York City-based Bristol-Myers Squibb Co. (BMS) under a WKSI shelf registration and three issues of notes immediately drawn down from this shelf. The ratings on the shelf are preliminary. All the new ratings are listed in the Ratings List at the end of this article. Amounts and rates for the three maturities will be determined by market conditions. We expect that proceeds from these issues will form part of the financing of the $5.3 billion acquisition of Amylin Pharmaceuticals Inc. as well as the costs of retiring Amylin debt and other transaction-related expenses, which will raise the
